Incyte gets much-needed boost as eczema cream trial hits tar...

US biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream in adults and adolescents aged 12 or above, sending its shares ticking up.

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Incyte's JAK inhibitor for GVHD fails phase 3 trial

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.

Incyte shares down sharply after phase 3 skin cancer trial f...

Trial tested epacadostat pill in combination with Merck & Co’s Keytruda

ASCO round up: Zytiga shines in frontline prostate role, Lox...

While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.

Lilly slumps after FDA rejects RA pill

Partner Incyte also hit after shock rejection.